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Nanoparticle-based photothermal therapy (PTT) has been widely investigated in cancer therapy as a rapid and 
minimally invasive tumor ablation technique. Over the past two decades, several reports utilizing nanoparticles 
for PTT of diverse tumor types in vitro and in vivo have been described. An emerging area of interest is the 
effect of PTT on the immune system during tumor therapy, since PTT not only causes tumor cell death, but can 
also release tumor antigens and endogenous adjuvants (e.g. heat shock proteins, damage-associated 
molecular patterns (DAMPs)) under certain conditions. These effects have the potential to increase tumor 
immunogenicity, which can trigger improved therapeutic responses. Engaging the immune system during PTT is 
important as it offers the potential for persistent treatment responses and immunological memory. 
Here, we describe a thermal “window” of immunogenic cell death (ICD) elicited by nanoparticle-based 
photothermal therapy (PTT) in an animal model of neuroblastoma. ICD is a highly favorable cell death 
phenotype that initiates an adaptive immune response and is associated with improved therapeutic outcomes in 
cancer.1 In studies 






tumors in the 
neuroblastoma 
model, we observed 
that PBNP-PTT 
conformed to the 
“more is better” 
paradigm, wherein 
higher doses of 
PBNP-PTT 
generated higher 
cell/local heating and 




survival. However, in vitro analysis of the biochemical correlates of ICD elicited by PBNP-PTT, namely ATP and 
high motility group box 1 protein (HMGB1) release and increased surface calreticulin expression, demonstrated 
that PBNP-PTT triggered a thermal window of ICD. Specifically, the aforementioned markers of ICD were highly 
expressed within an optimal temperature (thermal dose) window of PBNP-PTT (63.3-66.4 oC) as compared with 
higher (83.0-83.5 oC) and lower PBNP-PTT (50.7-52.7 oC) temperatures, which both yielded lower expression of 
ICD markers (Fig. 1A). Subsequent vaccination studies in the neuroblastoma model confirmed our in vitro 
findings wherein PBNP-PTT administered within the optimal temperature window (63.3-66.4 oC) resulted in long-
term survival (33.3% at 100 days) compared with PBNP-PTT administered within the higher (0%) and lower 
(20%) temperature ranges, and controls (0%) (Fig. 1B). Our findings demonstrate a tunable immune response 
to heat generated by PBNP-PTT, which should be critically engaged in the administration of PTT, both alone 
and when PTT is administered in combination with immune adjuvants (e.g. TLR agonists) and/or 
immunotherapies (e.g. immune checkpoint inhibitors) for maximizing its therapeutic benefits.  
REFERENCE: 1. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer 
and infectious disease. Nat Rev Immunol. Feb 2017;17(2):97-111.  
Figure 1. PBNP-PTT exhibits a thermal window of immunogenic cell death. A) Expression
of ICD markers (HMGB1, ATP, and Calreticulin) showing increased expression between 48-65
oC (gray band) in vitro. B) Long-term survival in mice vaccinated with Neuro2a cells treated with
different thermal doses of PBNP-PTT and subsequently challenged with Neuro2a cells
exhibiting maximum long-term survival for animals vaccinated with PBNP-PTT-treated cells at
~65 oC compared with animals in the lower (~51 oC) and higher (~83 oC) temperature groups; *
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